Ulcerative Colitis

The FDA has approved Eli Lilly’s Omvoh infusion/injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.

VANCOUVER, British Columbia — In a Healio video exclusive, Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial, in which more patients with ulcerative colitis achieved clinical remission on IV risankizumab vs. placebo.

VANCOUVER, British Columbia — In a Healio video exclusive, Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response at weeks 12 and 24 among patients with ulcerative colitis.

PRA023, an investigational antibody directed against tumor necrosis factor-like cytokine 1A, induced clinical remission at 12 weeks in significantly more patients with ulcerative colitis vs. placebo, according to data presented at UEG Week.

The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active ulcerative colitis, according to a company press release.

The FDA has denied a biologics license application from Alvotech for its biosimilar to ustekinumab, citing “certain deficiencies” at the company’s facility in Reykjavik, Iceland, according to the manufacturer.

The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe ulcerative colitis following induction therapy via IV administration of the biologic.

Adolescents and young adults with ulcerative colitis are at risk for poor adherence to maintenance treatment with 5-aminosalicylic acid in the first year, highlighting the importance of physician follow-up, data showed.

Patients with moderate to severe ulcerative colitis achieved critical clinical, endoscopic and histological outcomes on maintenance doses of upadacitinib compared with placebo, with no new safety risks reported, according to study results.

With inflammatory bowel disease on the rise in the South Asian community, patients face barriers to diagnosis and treatment, lack of insurance, stigmatization and low cultural competence from specialists — if a specialist can be found at all.